Financials?Due by end of next week I believe - Q2 - This was the Corporate update from 2 weeks ago - Hoping for some nice top line Revenue numbers - Lets get this SP moving in the right direction,
"
Management would also like to provide an update to its shareholders around the volatility of the stock and would like to address recent investor inquiries. The company has not deviated from its business plan announced on June 29, 2018, and believes it is executing on its business strategies in each division with new revenue opportunities being added on a consistent basis. Further, management believes some of the company's business strategies are in front of market trends that will soon be recognized by the market, particularly as legalization continues to trend in a favourable direction in the United States and Mexico. Due to recent developments with the U.S. Hemp Bill, the company has postponed plans of its previously announced Chinese facility expansion plans and has been focusing its resources and attention to the expected coming opportunities in the United States and Mexico.
On Dec. 6, 2017, the company announced the 100-per-cent acquisition of CN Pharma, located in Abbotsford, B.C., a pharmaceutical manufacturing company. The company believed that CN Pharma was in the latter stages of obtaining its licensed dealer status under the provisions of the Canadian Controlled Drugs and Substances Act; however, many changes to regulatory guidelines have caused a delay. CN Pharma has reapplied for its licensing under these new cannabis regulations and is ready for inspection. The company is hoping to receive additional feedback from Health Canada after inspection and believes CN Pharma remains in a position to obtain its licence. CN Pharma will only be paid the $6-million in stock upon successful completion of obtaining the licence.
The company is monitoring the developing regulations surrounding CBD in Canada and believes it will be in a position for the distribution of its products in this market as regulations continue to change. Currently, the company can supply CBD as an API (active pharmaceutical ingredient) to a licensed dealer in Canada from its subsidiary, BSPG Laboratories Ltd. The company strongly believes the United States and other foreign markets such as the United Kingdom and Brazil will surpass the market opportunities in Canada that are currently getting stock market attention, and, as a result, Isodiol will continue to put much of its focus on the U.S. and markets outside of Canada.
Finally, the company had previously announced its intention to uplist to a major U.S. exchange and this intention has not changed. The company continues to explore all of its options for a potential uplisting. Further updates on this matter will be provided as they are available."